Zyomyx Sells Protein Profiling Biochip System to Aventis | GenomeWeb

NEW YORK, March 6 - Zyomyx today said that Aventis has agreed to buy one of its Protein Profiling Biochip systems.

The tool consists of Zyomyx's first protein profiling biochip--called the Human Cytokine Biochip--as well as the Assay 1200 automated workstation and the Scanner 100 reader and data-analysis software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.